Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of ARB-001467 in Chronic HBV Patients on Nucleos(t)ide Analogue Therapy
2015-005136-18Phase 2Completed
- Sponsor
- Arbutus Biopharma Corporation
- Start
- Jan 2016
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ARB-1467 in Chronic Hepatitis B (CHB), sponsored by Arbutus Biopharma Corporation. Started Jan 2016; status: completed.
02
Drugs
ARB-1467
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2015-005136-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005136-18.